Indeed, inhibition of NFκB through adenoviral delivery of a modified form of IκB, a specific inhibitor of NFκB, has been reported to sensitize chemo-resistant tumours to the apoptotic potential of TNF-α and to the chemotherapeutic compound CPT-11, resulting in tumour regression [74]. The gene discussed is NFKB1; the disease is neoplasm.